Katalyze AI Raises $10.5M in Seed Funding Led by Bonfire Ventures

The round also saw participation from Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors including Gokul Rajaram and Farzad Soleimani.

The company plans to use the funding to expand its operations and support product development.

Katalyze helps pharmaceutical companies use AI agents to handle complex scientific and engineering tasks while making sure they follow strict industry regulations and compliance requirements.

The company is already seeing strong results. Instead of getting stuck in the pilot stage like many startups, Katalyze's platform is being used by five of the world's 20 largest pharmaceutical companies. So far, its software has supported the delivery of more than 10 million medication doses.

Read More:Bespoke Labs Raises $40M in Funding Led by Wing VC

For pharmaceutical companies, the biggest advantage is speed. In one early customer project, a complex operational analysis that normally took a year and cost between $4 million and $6 million was completed by Katalyze's AI agents in just 45 minutes.

One of the biggest challenges in the pharmaceutical industry is that important data is spread across many different systems, including manufacturing software, electronic lab records, and older business platforms such as SAP. This makes it difficult to access and use information efficiently.

Katalyze solves this by connecting these systems into a single, real-time platform. It creates a central source of trusted data that its AI agents use to investigate manufacturing issues and prepare quality reports. The platform also follows strict Good x Practice (GxP) standards and data security requirements, helping pharmaceutical companies use AI while staying compliant.

Sabya Dasgupta, Sanofi’s Global VP of R&D Data Platforms & Products, noted that Katalyze arrived ready for immediate, large-scale deployment. “What really separated Katalyze was that it was built for an enterprise like Sanofi from day one,” Dasgupta explained. “They had the security, the governance, the deployment story, everything we needed to scale this across R&D, not just run a pilot in one corner of the organization.”

Here’s what Brett Queener, a General Partner at Bonfire Ventures said: “Most AI in this category is a thin copilot bolted onto legacy tools. Katalyze went the other way and built real infrastructure. By putting a GxP-native context layer underneath autonomous agents, they let AI reason across the messy, fragmented data of pharma manufacturing and actually do the work. That’s the unlock the industry has been waiting for.”

“The pressure to get medicine to patients faster, and at lower cost, has never been higher, but the bar for accuracy in our industry is absolute,” said Reza Farahani, Co-Founder and CEO of Katalyze AI. “We built an agentic operating system where every answer is grounded in an immutable record, so teams can deploy agents that are right every time and cut lab and manufacturing cycles from quarters to weeks.”

About Katalyze AI

Founded in 2022 by Reza Farahani and Shreyas Becker, Katalyze AI develops an AI platform designed specifically for the pharmaceutical industry. The platform connects with existing lab and manufacturing systems, allowing AI-agents to handle complex tasks in drug development, and production. It also provides a secure and traceable system that meet's Good x Practice (GxP) standards, helping pharmaceutical companies use AI while staying compliant with industry regulations.

Read More:Standard Nuclear Appoints Don Moul to Board of Directors